MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Section: Allergy & Immunology
Allergy & Immunology

Use of Teplizumab to Modulate Stage 2 Type 1 Diabetes in Two Individuals With Autoimmune Polyendocrine Syndrome 1

MedXY Editorial TeamDec 30, 2025
case reportdiagnosistreatment

An overview of autoimmune polyendocrine syndrome type 1 with stage 2 type 1 diabetes treated using teplizumab shows glucose improvement in both individuals and transient pancreas volume increase with reduced effector T cells.

**Patient Information**
This report describes two adolescent individuals with autoimmune polyendocrine syndrome type 1 (APS-1) who developed stage 2 type 1 diabetes (T1D). The first individual, who was not initially diagnosed with APS-1, presented with symptoms prompting early investigation. She exhibited multiple autoimmune features including hypoparathyroidism, adrenal insufficiency, alopecia, and chronic mucocutaneous candidiasis. Her genetic background included compound heterozygous mutations (796C>T and 1337G>A) in the AIRE gene.

The second individual had a pre-existing diagnosis of APS-1, confirmed by homozygosity for the 796C>T mutation in AIRE. She demonstrated diverse autoimmune manifestations such as hypoparathyroidism, enteritis, vitiligo, hypothyroidism, and adrenal insufficiency.

Both patients were on various medications to manage their autoimmune conditions, detailed in supplementary materials. Laboratory evaluation revealed the presence of islet autoantibodies, though the antibody profiles varied between the two individuals.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Dual Remission of Atopic Dermatitis and Frequently Relapsing Nephrotic Syndrome With Dupilumab

Allergy & ImmunologyNov 4, 2026

Navigating Autoimmune Neutropenia in Adults: Diagnosis and Tailored Treatment Strategies

Allergy & ImmunologyNov 4, 2026

Povetacicept Shows Promising Interim Results in Phase 3 Trial for IgA Nephropathy

Allergy & ImmunologyOct 30, 2026
Loading comments...

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story